You are here: Home / Sites / Johns Hopkins Medical Institutions / Chan, Daniel

Chan, Daniel (Ph.D.)

PI, Johns Hopkins Medical Institutions, 410-955-2674

Contact Information

Fax: 443-287-6388
EDRN Principal Investigator

To update contact information, please visit the Data Management and Coordinating Center.

Open Protocols

Protocol Name Biomarkers Datasets
Clinical and Analytical Validation of Cancer Biomarkers: Developmental Studies 0 0
Clinical Utility of Urinary CD90 as a Biomarker for Prostate Cancer Detection 1 1
Development and Clinical Validation of Biomarkers for Prostate Cancer 0 0
Prediction rules for aggressive prostate cancer in AS population 0 0
Prostate-MRI 0 0
Upgrading Reference Set 0 0
Uterine Lavage 0 0

Closed Protocols

Protocol Name Biomarkers Datasets
Prostate Rapid Reference Set Application: Daniel Chan/Patty Beckman- JHU/University of Minnesota (2007) 4 0
Prostate Reference Set Application: proPSA-Dan Chan-JHU (2008) 2 0
EDRN-WHI Pre-Clinical Colon Ca Specimens 0 9
Liver Rapid Reference Set Application: Hemken - Abbott (2015) 0 0
PCA3 Reference Set Application: T2-Erg-Martin Sanda-Emory (2014) 2 0
PCA3 Validation Study and Urinary Reference Set 2 0
Prostate Rapid Pre-Validation Set 6 0


Publication Name PubMed ID Journal
A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. 21419439 J. Urol.
Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns. 19035787 J. Proteome Res.
Suppression of annexin A11 in ovarian cancer: implications in chemoresistance. 19484149 Neoplasia
Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers. 19157448 J. Urol.
A unique proteolytic fragment of alpha1-antitrypsin is elevated in ductal fluid of breast cancer patient. 19902353 Breast Cancer Res. Treat.
The road from discovery to clinical diagnostics: lessons learned from the first FDA-cleared in vitro diagnostic multivariate index assay of proteomic biomarkers. 20962299 Cancer Epidemiol. Biomarkers Prev.
Tyramide signal amplification for antibody-overlay lectin microarray: a strategy to improve the sensitivity of targeted glycan profiling. 21133419 J. Proteome Res.
Identification of glycoproteins containing specific glycans using a lectin-chemical method. 25837443 Anal. Chem.
Multiplexed Targeted Mass Spectrometry-Based Assays for the Quantification of N-Linked Glycosite-Containing Peptides in Serum. 26451657 Anal. Chem.
GPQuest: A Spectral Library Matching Algorithm for Site-Specific Assignment of Tandem Mass Spectra to Intact N-glycopeptides. 25945896 Anal. Chem.
Integrated glycoprotein immobilization method for glycopeptide and glycan analysis of cardiac hypertrophy. 26378618 Anal. Chem.
Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men. 25636659 J. Urol.
Tissue proteomics using chemical immobilization and mass spectrometry. 25283129 Anal. Biochem.
The prostate health index selectively identifies clinically significant prostate cancer. 25463993 J. Urol.
Serum fucosylated prostate-specific antigen (PSA) improves the differentiation of aggressive from non-aggressive prostate cancers. 25553114 Theranostics
Network biology in medicine and beyond. 25140061 Circ Cardiovasc Genet
Comprehensive analysis of protein glycosylation by solid-phase extraction of N-linked glycans and glycosite-containing peptides. 26571101 Nat. Biotechnol.
Cancer proteomics: in pursuit of "true" biomarker discovery. 16214905 Cancer Epidemiol. Biomarkers Prev.
Proteomic cancer biomarkers from discovery to approval: it's worth the effort. 24646122 Expert Rev Proteomics
Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%. 15596190 Urology
Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by a surface-enhanced laser desorption/ionization-based immunoassay. 16574760 Clin. Chem.
Detection of prostate cancer using serum proteomics pattern in a histologically confirmed population. 15076276 J. Urol.
ProteinChips: the essential tools for proteomic biomarker discovery and future clinical diagnostics. 16309362 Clin. Chem. Lab. Med.
Identification of biomarkers for breast cancer in nipple aspiration and ductal lavage fluid. 16322290 Clin. Cancer Res.
Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients. 17982121 Clin. Cancer Res.
Enzymes and related proteins as cancer biomarkers: a proteomic approach. 17382922 Clin. Chim. Acta
Cancer biomarker discovery in plasma using a tissue-targeted proteomic approach. 17932335 Cancer Epidemiol. Biomarkers Prev.
Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. 17981926 Clin. Chem.
Integrated analyses of proteins and their glycans in a magnetic bead-based multiplex assay format. 23099556 Clin. Chem.
Validation of a multiplex immunoassay for serum angiogenic factors as biomarkers for aggressive prostate cancer. 22722017 Clin. Chim. Acta
Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. 17920110 Gynecol. Oncol.
Expression and clinicopathological significance of oestrogen-responsive ezrin-radixin-moesin-binding phosphoprotein 50 in breast cancer. 17593079 Histopathology
Application of traditional clinical pathology quality control techniques to molecular pathology. 18258922 J Mol Diagn
Biomarkers in prostate cancer: what's new? 24626128 Curr Opin Oncol
An integrated proteomic and glycoproteomic approach uncovers differences in glycosylation occupancy from benign and malignant epithelial ovarian tumors. 28491011 Clin Proteomics
Glycoproteomic analysis of bronchoalveolar lavage (BAL) fluid identifies tumor-associated glycoproteins from lung adenocarcinoma. 23802180 J. Proteome Res.
Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. 12597929 Urology
A highly sensitive targeted mass spectrometric assay for quantification of AGR2 protein in human urine and serum. 24251762 J. Proteome Res.
AISAIC: a software suite for accurate identification of significant aberrations in cancers. 24292941 Bioinformatics
Analysis of serum protein glycosylation by a differential lectin immunosorbant assay (dLISA). 24015777 Clin Proteomics
Longitudinal assessment of urinary PCA3 for predicting prostate cancer grade reclassification in favorable-risk men during active surveillance. 28417979 Prostate Cancer Prostatic Dis.
Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 men. 12384158 Urology
Detection and verification of glycosylation patterns of glycoproteins from clinical specimens using lectin microarrays and lectin-based immunosorbent assays. 21975078 Anal. Chem.
Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer. 27743489 BJU Int.
Updating risk prediction tools: a case study in prostate cancer. 22095849 Biom J
Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml. 12913682 J. Urol.

To update protocols, publications, biomarkers, or science data, please contact the Informatics Center.


Dept. of Pathology, 1550 Orleans St., Room 3M05, CRB2 Building
Johns Hopkins Medical Institutions

To update addresses, please visit the Data Management and Coordinating Center.

🔜 Data-Sci Workshop
The EDRN Biomarker Data Science Workshop is coming this August, 2020. More details available soon.
Announcement 03/17/2020

The EDRN Registration page will be available soon to register for the 35th EDRN Steering Committee Meeting, now scheduled to take place from June 30-July 2, 2020, in Tempe, AZ.

This icon signifies that something is happening and we kindly ask you to please wait